索利那新联合依帕司他治疗2型糖尿病合并膀胱过度活动症的疗效观察

发布时间：2018-07-16 20:51

【摘要】：目的观察索利那新联合依帕司他治疗T2DM合并膀胱过度活动症(OAB)的疗效和安全性。方法选取T2DM合并OAB患者80例,随机分为对照组(Con)24例,依帕司他组29例,索利那新+依帕司他组27例。Con组予常规膀胱训练、降糖、降压、调脂、营养神经等一般治疗。在一般治疗的基础上,依帕司他组口服依帕司他50 mg,3次/d。索利那新+依帕司他组口服索利那新5 mg,1次/d,依帕司他50 mg,3次/d。观察12周,记录排尿日记、OAB自我评价量表(OABSS)评分、最大尿流率(Qmax)、平均尿流率(Qave)、排尿量(VV)。结果索利那新+依帕司他组治疗后24 h排尿次数、夜尿次数、尿急次数、尿失禁次数、OABSS评分均低于Con组和依帕司他组,Qmax、Qave、VV高于Con组和依帕司他组(P0.05);依帕司他组治疗后OABSS评分低于Con组,VV高于Con组(P0.05);索利那新+依帕司他组总有效率高于依帕司他组和Con组(92.6%vs69.0%vs41.7%,P0.05)。结论索利那新联合依帕司他治疗T2DM合并OAB的疗效确切。
[Abstract]:Objective To observe the efficacy and safety of corelna combined with esprolac in the treatment of T2DM combined with hyperactivity of bladder (OAB). Methods 80 patients with OAB were randomly divided into 24 cases of control group (Con), 29 cases in the group of esproactive and 27 cases of group.Con in group.Con of corelna + elaxin and the group of IVA. In general treatment, on the basis of general treatment, the group of the IVA group took orally 50 mg of IVA, 3 /d. corelino + elaxin group, 1 /d, 50 mg and 3 /d. for 12 weeks, recorded the diaries of urination, OAB self evaluation scale (OABSS) score, maximum urinary flow rate (Qmax), average urinary flow rate (Qave), urination volume (VV). The number of urinating times, the number of nocturnal times, the times of urination, the frequency of urination, the number of incontinence, and the OABSS score of the group of 24 h after the treatment were lower than that of group Con and the group of the IVA, Qmax, Qave, VV were higher than that of the Con group and the group of the IVA (P0.05); the OABSS score of the IVA group was lower than the Con group, and the VV was higher than that of the Con group. The rate was higher than that of the Con group (92.6%vs69.0%vs41.7%, P0.05). Conclusion the efficacy of the combination of orlistat and ellistat is effective in the treatment of T2DM complicated with OAB.
【作者单位】：辽宁省人民医院内分泌科;青海省湟中县人民医院内三科;
【分类号】：R587.2;R694.5

【相似文献】